Empagliflozin's CV Gains Explored in Diabetics With, Without HFEmpagliflozin's CV Gains Explored in Diabetics With, Without HF
Given the specter of associated heart failure with some antidiabetic medications, deeper analysis of the recently reported EMPA-REG OUTCOME trial of the SGLT2 inhibitor may reassure. Heartwire from Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Diabetes | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance | SGLT2 Inhibitors